Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Negro

Showing results (301-310 of 334) with videos related to

Pageof 34
Sort By:
Cancers|July 27, 2024
Effect of Direct Acting Antiviral Drugs on the Occurrence and Recurrence of Intra- and Extra-Hepatic Malignancies in Patients with Chronic Hepatitis C Virus InfectionPompilia Radu, Chiara Becchetti, Jonas Schropp, et al.
Hepatology (Baltimore, Md.)|January 3, 2014
Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trialZobair Younossi, Francesco Negro, Lawrence Serfaty, et al.
Swiss Medical Weekly|July 22, 2010
Treatment of hepatitis C in HCV mono-infected and in HIV-HCV co-infected patients: an open-labelled comparison studyJean-Jacques Gonvers, Markus H Heim, Matthias Cavassini, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|September 17, 2013
Elderly age is not a negative predictive factor for virological response to therapy with pegylated interferon-α and ribavirin in chronic hepatitis C virus patientsPascal Frei, Anna-Kathrin Leucht, Ulrike Held, et al.
The Journal of Infectious Diseases|September 9, 2006
Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infectionAna I Romero, Martin Lagging, Johan Westin, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 17, 2018
Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant CandidatesZobair Younossi, Maria Stepanova, Janus P Ong, et al.
BMC Gastroenterology|February 2, 2012
Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled studyGeert Bezemer, Arthur R Van Gool, Elke Verheij-Hart, et al.
Plos One|February 26, 2013
Impact of soluble CD26 on treatment outcome and hepatitis C virus-specific T cells in chronic hepatitis C virus genotype 1 infectionJonas Söderholm, Jesper Waldenström, Galia Askarieh, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|March 7, 2017
A systematic review and meta-analysis of HCV clearanceEmeline Gauthiez, Ines Habfast-Robertson, Sina Rüeger, et al.
Hepatology (Baltimore, Md.)|November 30, 2006
IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infectionMartin Lagging, Ana I Romero, Johan Westin, et al.
Pageof 34

Showing results (301-310 of 334) with videos related to

Sort By:
Pageof 34
Cancers|July 27, 2024
Effect of Direct Acting Antiviral Drugs on the Occurrence and Recurrence of Intra- and Extra-Hepatic Malignancies in Patients with Chronic Hepatitis C Virus InfectionPompilia Radu, Chiara Becchetti, Jonas Schropp, et al.
Hepatology (Baltimore, Md.)|January 3, 2014
Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trialZobair Younossi, Francesco Negro, Lawrence Serfaty, et al.
Swiss Medical Weekly|July 22, 2010
Treatment of hepatitis C in HCV mono-infected and in HIV-HCV co-infected patients: an open-labelled comparison studyJean-Jacques Gonvers, Markus H Heim, Matthias Cavassini, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|September 17, 2013
Elderly age is not a negative predictive factor for virological response to therapy with pegylated interferon-α and ribavirin in chronic hepatitis C virus patientsPascal Frei, Anna-Kathrin Leucht, Ulrike Held, et al.
The Journal of Infectious Diseases|September 9, 2006
Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infectionAna I Romero, Martin Lagging, Johan Westin, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 17, 2018
Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant CandidatesZobair Younossi, Maria Stepanova, Janus P Ong, et al.
BMC Gastroenterology|February 2, 2012
Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled studyGeert Bezemer, Arthur R Van Gool, Elke Verheij-Hart, et al.
Plos One|February 26, 2013
Impact of soluble CD26 on treatment outcome and hepatitis C virus-specific T cells in chronic hepatitis C virus genotype 1 infectionJonas Söderholm, Jesper Waldenström, Galia Askarieh, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|March 7, 2017
A systematic review and meta-analysis of HCV clearanceEmeline Gauthiez, Ines Habfast-Robertson, Sina Rüeger, et al.
Hepatology (Baltimore, Md.)|November 30, 2006
IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infectionMartin Lagging, Ana I Romero, Johan Westin, et al.
Pageof 34